Could JAK inhibitors increase survival in people with myelofibrosis, even though genetic mutations vary from patient to patient? Dr. Alessandro Vannuchi, an MPN researcher from University of Florence in Italy, discusses study results indicating that treatment with JAK inhibitors may improve survival and quality of life for people with myelofibrosis. Dr. Vannuchi explains how this research shows a positive impact on spleen volume, disease symptoms and survival, regardless of the molecular status of the patient.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…